DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the Sudarshan Pharma Industries Ltd (SUDARSHAN) share price today?

Sudarshan Pharma Industries Ltd (SUDARSHAN) is trading at ₹42.31 on the BSE, up 3.09% on the day. Source: DocStoX.

What is the PE ratio of Sudarshan Pharma Industries Ltd?

Sudarshan Pharma Industries Ltd has a price-to-earnings (PE) ratio of 64.1 in the Commodities sector.

What is the market capitalisation of Sudarshan Pharma Industries Ltd?

Sudarshan Pharma Industries Ltd has a market capitalisation of approximately ₹988 crore.

Sudarshan Pharma Industries Ltd

SUDARSHAN·BSE·Commodities

₹42.31▲ +1.27 (+3.09%)

Commodities · Chemicals & Petrochemicals

Carries meaningful debt — watch the balance sheet

Day₹41.03

₹42.79

52W₹19

₹42101%

Open

₹41.04

High

₹42.79

Low

₹41.03

Prev Close

₹41.04

Volume

80.0K

VWAP

₹41.97

Snapshot

Key fundamentals

Market Cap

₹988 Cr

P/E Ratio

64.11Expensive

P/B Ratio

6.37

EPS

₹0.66

Book Value

₹6.44

ROE

12.13%Average

ROCE

16.00%Decent

Dividend Yield

0.73%

Debt / Equity

1.84High

Face Value

₹1.00

52W High

₹42.16

52W Low

₹18.50

Sector

Commodities

Industry

Chemicals & Petrochemicals

Avoid

None moatVery High uncertainty

Fair value estimate

₹12

▼ 71.3%downside

Trading at ₹42 — 71% above our estimate

BearFair valueBull

₹6₹12₹26

/100

Business quality — Watch the fundamentals

Growth 50Profitability 21Efficiency 40Valuation 4

Plain English

Our view

Carries meaningful debt — watch the balance sheet
Promoters hold a controlling stake
High leverage — debt exceeds 1.5× equity

Strengths

Promoters hold a controlling stake

Risks

High leverage — debt exceeds 1.5× equity
Expensive — trades at 64× earnings

How we got there

Fair value methods

Residual income

12% ROE fading to 15% over ~3 yrs, on ₹6 book

₹6

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹26

Analyst target

No analyst coverage

—

Blended fair value₹12

What the numbers say

Investment thesis

Bull case

Promoters hold a controlling stake

Bear case

High leverage — debt exceeds 1.5× equity
Expensive — trades at 64× earnings

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

64.1Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

12.1%Average

Above 15% is considered healthy for Indian equities

ROCE

16.0%Decent

Above 18% means capital is working hard

Debt/Eq

1.84High

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹988 Cr

P/B

6.37

EPS

₹0.66

Div Yield

0.73%

What changed

Recent changes

Foreign investors+0.2% stake last quarter

What matters

News impact

Overview

Valuation

Expensive

P/E 64.1×

Growth

Strong

+15% rev CAGR

Profitability

Healthy

12.1% ROE

Financial health

Leveraged

D/E 1.84

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover₹33.58L Cr

Trades20

VWAP₹41.97

Face value₹1.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+15.1%

+29.5%

10Y

—

Profit

+49.1%

+50.6%

10Y

—

EPS

+154.1%

+76.2%

10Y

—

Profile

Pros

Company is expected to give good quarter
Company has delivered good profit growth of 54.2% CAGR over last 5 years
Company's working capital requirements have reduced from 44.1 days to 17.1 days

Watch-outs

Cons

Stock is trading at 6.37 times its book value
Though the company is reporting repeated profits, it is not paying out dividend

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Foreign investors bought 0.17 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

57%

Promoter

Promoters

57.4%0.00

Public

16.4%-0.47

FII / FPI

19.9%+0.17

DII

0.0%0.00

Others

6.3%

Total shareholders

1,346-61 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter57.39%

FII19.95%

Government0.05%

Public16.41%

Others6.20%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 2008, Sudarshan Pharma Industries Ltd manufactures API and Pharmaceutical Items. It also trades in Chemicals and Solvents[1]